India Nucleic Acid Therapeutics Cdmo Market Size & Outlook
The nucleic acid therapeutics cdmo market in India is expected to reach a projected revenue of US$ 3,270.5 million by 2033. A compound annual growth rate of 16.8% is expected of India nucleic acid therapeutics cdmo market from 2026 to 2033.
Every answer starts with GVR research, and every figure is cited.Explore Prism AI ↗
India nucleic acid therapeutics cdmo market highlights
The India nucleic acid therapeutics cdmo market generated a revenue of USD 948.6 million in 2025 and is expected to reach USD 3,270.5 million by 2033.
The India market is expected to grow at a CAGR of 16.8% from 2026 to 2033.
In terms of segment, rna-based therapies was the largest revenue generating type in 2025.
RNA-based Therapies is the most lucrative type segment registering the fastest growth during the forecast period.
Nucleic acid therapeutics cdmo market data book summary
Market revenue in 2025
USD 948.6 million
Market revenue in 2033
USD 3,270.5 million
Growth rate
16.8% (CAGR from 2026 to 2033)
Largest segment
Rna-based therapies
Fastest growing segment
RNA-based Therapies
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
RNA-based Therapies, Gene Therapy
Key market players worldwide
Catalent Inc, Thermo Fisher Scientific Inc, Lonza Group Ltd, FUJIFILM Holdings Corp, Charles River Laboratories International Inc, Eurofins Scientific SE, PerkinElmer, Oxford Biomedical Research, Danaher Corp
Other key industry trends
In terms of revenue, India accounted for 5.4% of the global nucleic acid therapeutics cdmo market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China nucleic acid therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2033.
China is the fastest growing regional market in Asia Pacific and is projected to reach USD 4,816.7 million by 2033.
The nucleic acid therapeutics CDMO market in India is expected to grow at rapid pace over the forecast period. Growth in the country can be attributed to the availability of low-cost labor, low manufacturing costs, considerable demand for high-quality medications, and the presence of WHO cGMP-compliant facilities & a skilled workforce.
Furthermore, in 2019, the Indian Council of Medical Research (ICMR) recognized the potential for gene therapy. It has published a set of clinical guidelines that focus on a range of issues, from ethical clinical trials to regulation & production.
This factor has increased the interest of pharmaceutical and biotechnology in nucleic acid therapeutics, leading to the adoption of numerous strategies initiatives & product innovations and boosting CDMO demand in India.
India Nucleic Acid Therapeutics CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Nucleic Acid Therapeutics CDMO Market Outlook will help companies and investors design strategic landscapes.
Rna-Based Therapies was the largest segment with a revenue share of 75.98% in 2025.
Horizon Databook has segmented the India nucleic acid therapeutics cdmo market based on rna-based therapies, gene therapy covering the revenue growth of each sub-segment from 2021 to 2033.
The nucleic acid therapeutics CDMO market in India is expected to grow at rapid pace over the forecast period. Growth in the country can be attributed to the availability of low-cost labor, low manufacturing costs, considerable demand for high-quality medications, and the presence of WHO cGMP-compliant facilities & a skilled workforce.
Furthermore, in 2019, the Indian Council of Medical Research (ICMR) recognized the potential for gene therapy. It has published a set of clinical guidelines that focus on a range of issues, from ethical clinical trials to regulation & production.
This factor has increased the interest of pharmaceutical and biotechnology in nucleic acid therapeutics, leading to the adoption of numerous strategies initiatives & product innovations and boosting CDMO demand in India.
India Nucleic Acid Therapeutics Cdmo Market Type Outlook (Revenue, USD Million , 2021-2033)
Gene Therapy
RNA-based Therapies
India Nucleic Acid Therapeutics Cdmo Market Service Outlook (Revenue, USD Million , 2021-2033)
Process Development and Optimization
Manufacturing Services
Analytical and Quality Control Services
Others
India Nucleic Acid Therapeutics Cdmo Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceutical Companies
Government & Academic Research Institutes
Biotech Companies
India Nucleic Acid Therapeutics Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
Rare Diseases
Genetic Disorders
Infectious Diseases
Others
Reasons to subscribe to Nucleic Acid Therapeutics CDMO Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Nucleic Acid Therapeutics CDMO Market Outlook databook
Our clientele includes a mix of Nucleic Acid Therapeutics CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India Nucleic Acid Therapeutics CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into India Nucleic Acid Therapeutics CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
India Nucleic Acid Therapeutics Cdmo Market, 2021-2033 (US$M)